18 March 2019 - GW Pharmaceuticals today announced that GW Research Ltd. has entered into a definitive agreement to sell its rare paediatric disease priority review voucher for $105,000,000. 

GW was awarded the voucher under a U.S. FDA program intended to encourage the development of treatments for rare paediatric diseases. GW Research Ltd. received the PRV when Epidiolex (cannabidiol) was approved by the FDA for the treatment of seizures associated with Lennox-Gastaut Syndrome or Dravet syndrome, two rare, severe childhood-onset epilepsies. 

The transaction remains subject to customary closing conditions, including anti-trust review.

Read GW Pharmaceuticals press release